Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
Authors:
- 1 January 2015
- journal article
- Vol. 113, T8
Abstract
To evaluate whether half-dose verteporfin photodynamic therapy (PDT) is better than natural history for the treatment of central serous chorioretinopathy (CSC). Retrospective review of consecutive CSC patients treated with half-dose verteporfin PDT or untreated with observation and a minimum follow-up of 36 months. The main outcome measures included mean change in visual acuity and CSC recurrence. Survival analysis was performed to compare the CSC recurrence rates between the two groups. A total of 192 eyes of 192 patients were included; 75 eyes were treated with half-dose verteporfin PDT and 117 were untreated. The mean follow-up duration was 74.1 months. At the last follow-up, the mean logMAR visual acuity was significantly better in the half-dose verteporfin PDT group compared with the untreated control group (P=.005). The mean visual improvement of the half-dose verteporfin PDT group at the last follow-up was 1.8 lines, compared with 0.0 line in the untreated control group (P<.001). Recurrence of CSC developed in 15 eyes (20%) in the half-dose verteporfin PDT group compared with 63 eyes (53.8%) in the untreated control group (P<.001). Survival analysis demonstrated that eyes treated with half-dose verteporfin PDT were significantly less likely to develop CSC recurrence compared with untreated controls (P<.001). Regression analysis showed that half-dose verteporfin PDT was the only significant factor in reducing the risk of CSC recurrence. Half-dose verteporfin PDT for the treatment of CSC resulted in significantly better visual acuity outcomes and lower recurrence rate in the long term compared with untreated controls.Keywords
This publication has 173 references indexed in Scilit:
- PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHYRetina, 2009
- Severe choroidal ischemia following Photodynamic Therapy for pigment epithelial detachment and chronic central serous chorioretinopathyJapanese Journal of Ophthalmology, 2009
- Sudden loss of visual acuity following intra-articular steroid injection in to the knee joint: a case reportCases Journal, 2008
- The potential role of testosterone in central serous chorioretinopathyBritish Journal of Ophthalmology, 2006
- Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyBritish Journal of Ophthalmology, 2006
- Choroidal Hemodynamic Changes during Isometric Exercise in Patients with Inactive Central Serous ChorioretinopathyInvestigative Ophthalmology & Visual Science, 2005
- Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapyAmerican Journal of Ophthalmology, 2004
- CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHYRetina, 2003
- INDOCYANINE GREEN VIDEOANGIOGRAPHY OF OLDER PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHYRetina, 1996
- Ulcerative colitis complicated by idiopathic central serous chorioretinopathy with bullous retinal detachmentDigestive Diseases and Sciences, 1985